JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1995; 26:1741-1746
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, M.
Right arrow Articles by Picard, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, M.
Right arrow Articles by Picard, M.

Improvement of transthoracic pulmonary venous flow Doppler signal with intravenous injection of sonicated albumin

MJ Williams, BM McClements, and MH Picard

Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Boston 02114, USA.

OBJECTIVES. This study was performed to determine whether intravenous injection of a sonicated albumin echocardiographic contrast agent (Albunex) improved the quality of the transthoracic pulmonary venous flow Doppler signal. BACKGROUND. Previous studies have shown that transesophageal echocardiography provides pulmonary venous flow Doppler signals superior in quality to those seen with transthoracic echocardiography, which are of limited quality in up to 25% of patients. METHODS. Twenty-one patients underwent transthoracic pulsed wave Doppler examination of pulmonary venous flow before, during and after two doses of Albunex ranging from 0.08 ml/kg (low dose) to 0.22 ml/kg (high dose). In addition, five patients underwent transesophageal examination of pulmonary venous flow before and after a 0.08-ml/kg dose of Albunex. The efficacy of the contrast injection was determined using a score that graded the quality of the three components of the pulmonary venous Doppler signal from 0 to 3 (0 = no visible signal; 3 = optimal signal). RESULTS. Albunex enhanced the quality of the pulmonary venous Doppler signal from baseline (score 3.9 +/- 1.8 [mean +/- SD]) and at both low (score 5.1 +/- 2.2, p < 0.05) and high doses (score 5.6 +/- 2, p < 0.001). Transthoracic pulmonary venous flow velocities were increased, and peak flow velocity ratios were unchanged, after injection of contrast agent. The contrast-enhanced variables showed good agreement with transesophageal flow velocities. CONCLUSIONS. Albunex improves the quality of the transthoracic pulmonary venous Doppler signal, thus allowing improved accuracy of measurement. This approach appears to be effective for increasing the quality of data obtained from the transthoracic examination.


This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
D. Mukerjee, D. St. George, C. Knight, J. Davar, A. U. Wells, R. M. Du Bois, C. M. Black, and J. G. Coghlan
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis
Rheumatology, April 1, 2004; 43(4): 461 - 466.
[Abstract] [Full Text] [PDF]


Home page
Eur J EchocardiogrHome page
A Olariu, E Wellnhofer, M Grafe, and E Fleck
Non-invasive estimation of left ventricular end-diastolic pressure by pulmonary venous flow deceleration time
Eur J Echocardiogr, September 1, 2003; 4(3): 162 - 168.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1995 by the American College of Cardiology Foundation.